Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Free In-Person Regional Events Focused on Oncology and Population Health

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology : Episode 7

Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

March 28, 2025

Opinion

Video

Experts discuss what partnerships between academic and community settings look like with regard to bispecifics, highlighting the role academic centers play in supporting community practices with bispecific therapy protocols.

EP: 1.Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

EP: 2.Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

EP: 3.How Bispecific Antibodies Are Reshaping Cancer Care

EP: 4.Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

EP: 5.Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

EP: 6.Overcoming Key Operational Challenges in Integrating Bispecific Therapies

Now Viewing

EP: 7.Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

EP: 8.Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

EP: 9.Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy

EP: 10.Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

EP: 11.Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

EP: 12.Payer and Reimbursement Considerations for Bispecific Therapies

EP: 13.Emerging Therapeutic Areas for Bispecific Antibodies

EP: 14.Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

EP: 15.Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Video content above is prompted by the following:

What do partnerships look like between academic and community settings with regard to bispecifics?

What role do academic centers play in supporting community practices with bispecific therapy protocols?

Related Content

PCOC 2025 to Bring More Experts, More Engagement Than Ever

September 24th 2025

Article

Explore cutting-edge discussions on patient-centered oncology, value-based care, AI innovations, and survivorship strategies Thursday and Friday at PCOC 2025 in Nashville.

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

July 24th 2025

Podcast

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

Listen

Female patients with chronic spontaneous urticaria consistently experienced a more severe and burdensome disease course compared with their male counterparts. | Image Credit: Cuoregentile - stock.adobe.com

CSU More Burdensome in Female Patients, Especially in Midlife

September 20th 2025

Article

Female patients with chronic spontaneous urticaria (CSU) face greater disease severity and burdens, particularly in midlife, a study found.

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

December 23rd 2024

Podcast

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Listen

Atopic dermatitis | Image Credit: © DOC RABE Media-stock.adobe.com

Rocatinlimab AD Combo Therapy Safe, Effective Over 24 Weeks

September 19th 2025

Article

Findings from the ROCKET-SHUTTLE trial reveal the benefits of combining the anti-OX40 monoclonal antibody with topical therapies for atopic dermatitis.

Myasthenia gravis diagnosis | Image Credit: © Andrii-stock.adobe.com

Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis

September 18th 2025

Article

Efgartigimod shows promising early response in generalized myasthenia gravis, especially in patients with short disease duration and severe bulbar symptoms.

Related Content

PCOC 2025 to Bring More Experts, More Engagement Than Ever

September 24th 2025

Article

Explore cutting-edge discussions on patient-centered oncology, value-based care, AI innovations, and survivorship strategies Thursday and Friday at PCOC 2025 in Nashville.

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

July 24th 2025

Podcast

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

Listen

CSU More Burdensome in Female Patients, Especially in Midlife

September 20th 2025

Article

Female patients with chronic spontaneous urticaria (CSU) face greater disease severity and burdens, particularly in midlife, a study found.

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

December 23rd 2024

Podcast

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Listen

Rocatinlimab AD Combo Therapy Safe, Effective Over 24 Weeks

September 19th 2025

Article

Findings from the ROCKET-SHUTTLE trial reveal the benefits of combining the anti-OX40 monoclonal antibody with topical therapies for atopic dermatitis.

Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis

September 18th 2025

Article

Efgartigimod shows promising early response in generalized myasthenia gravis, especially in patients with short disease duration and severe bulbar symptoms.

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777